Skip to content

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting Ops

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting Ops

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting Ops

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting Ops

CT1812

Why The Best Biotech Leaders Take It Personally

Why The Best Biotech Leaders Take It Personally
Life Science Leader
By: Lisa Ricciardi
May 20, 2026

Why The Best Biotech Leaders Take It Personally Read More »

Transforming Neurodegenerative Disease Treatment

Transforming Neurodegenerative Disease Treatment
Fierce Biotech
With: Irena Luo
May 18, 2026

Transforming Neurodegenerative Disease Treatment Read More »

Blocking Toxic Oligomers: The Science and Strategy Behind Zervimesine

Blocking Toxic Oligomers: The Science and Strategy Behind Zervimesine
Psychiatric Times
May 11, 2026

Blocking Toxic Oligomers: The Science and Strategy Behind Zervimesine Read More »

Slowing Progression with Zervimesine in Dementia with Lewy Bodies

Slowing Progression with Zervimesine in Dementia with Lewy Bodies
Psychiatric Times
May 8, 2026

Slowing Progression with Zervimesine in Dementia with Lewy Bodies Read More »

Zervimesine Slows Symptom Progression at 6 Months in Dementia with Lewy Bodies

Zervimesine Slows Symptom Progression at 6 Months in Dementia with Lewy Bodies
Healio Neurology
By: Isabella Hornick
April 30, 2026

Zervimesine Slows Symptom Progression at 6 Months in Dementia with Lewy Bodies Read More »

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
MarketBeat
April 13, 2026

Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans Read More »

Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia with Lewy Bodies

Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia with Lewy Bodies
Neurology Live
By: Noah Stansfield
March 24, 2026

Zervimesine Demonstrates Symptom Slowing in Phase 2 SHIMMER Trial for Dementia with Lewy Bodies Read More »

AD/PD 2026 | Findings from the Phase IIa SHIMMER trial of zervimesine in mild-to-moderate DLB

AD/PD 2026 | Findings from the Phase 2a SHIMMER trial of zervimesine in mild-to-moderate DLB
Video Journal of Dementia
March 10, 2026

AD/PD 2026 | Findings from the Phase IIa SHIMMER trial of zervimesine in mild-to-moderate DLB Read More »

Cognition lengthens Zervimesine program in DLB

Cognition lengthens Zervimesine program in DLB
Bio Tuesdays
February 6, 2026

Cognition lengthens Zervimesine program in DLB Read More »

Type C Meeting with FDA Completed for Zervimesine in Dementia with Lewy Bodies

Type C Meeting With FDA Completed for Zervimesine in Dementia With Lewy Bodies
By: Jessica Walters
Psychiatric Times
January 27, 2026

Type C Meeting with FDA Completed for Zervimesine in Dementia with Lewy Bodies Read More »

1 2 … 6 Next →

Linkedin-in X-twitter

Terms of Use
Privacy Policy
Careers

FCOI Policy
Contact us

Copyright© 2025 Cognition Therapeutics All rights reserved

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon.

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org